NHMRC recommends puberty blockers remain an option for trans youth
Australia's National Health and Medical Research Council released interim advice recommending puberty blockers remain a conditional clinical option for some trans and gender diverse people under 18, with public consultation closing in January.
Newsnibs Staff
- 2026-11-17
- Updated 6:32 AM UTC
(Canberra, Australia)
Australia's National Health and Medical Research Council released interim national advice on Monday recommending that puberty blockers remain a clinical option for some trans and gender diverse people under 18 with gender incongruence. The recommendation is conditional, made using the GRADE approach, and depends on shared decision-making between patients, carers and clinicians. The advice is non-binding and open for public consultation, which closes in January.
The council rates the evidence on benefits and harms as low certainty. Its review covered 15 non-randomised studies, a limit it attributes to the ethical and practical difficulty of running randomised controlled trials in paediatric populations. Within that evidence, serious adverse events were rare, and the committee noted the medication may improve psychosocial functioning and reduce suicidality. It found no eligible evidence on fertility or bone health. It concluded that the potential benefits likely outweigh the risks for specific patients, and that treatment can be considered for young people with or without distress.
The council explicitly rejected "wait and see" models, saying that withholding care can negatively affect a young person's physical and mental health. It describes gender incongruence as a clinical difference between a person's gender and the sex recorded at birth, and "not a mental health disorder". Its guidance tells doctors to prioritise the young person's "best interest and wellbeing" and to respect their autonomy. A diagnosis of distress is not required for treatment.
The federal government commissioned the work after Queensland and the Northern Territory restricted puberty blockers in their public hospitals. The review took a year and examined international evidence. Queensland's ban took effect in January 2025, and the state ordered an independent review by psychiatrist Ruth Vine. It has said it will keep its pause in place until 2031, pending results of the UK's PATHWAYS trial. Both state and territory governments have already ruled out changing their bans.
Other countries have also moved to restrict the drugs. The United States, the United Kingdom and New Zealand have adopted restrictions, and England's 2024 Cass Review recommended limiting treatment to research settings. New Zealand's High Court overturned that country's restrictions in October. Puberty blockers have been used in medical settings since the 1970s and in gender-affirming care since the 1990s, and the Pharmaceutical Benefits Scheme covers them for cisgender patients.
The numbers receiving the treatment in Australia are small. As of July, 58 young people in Western Australia and 77 in Queensland were taking puberty suppressants, about 0.007% of the combined under-18 population of those states. The draft also identifies unresolved barriers to access, including long waiting lists and treatment costs that can exceed A$5,000 a year. The council's full national clinical guidelines, expected in 2028, will address other aspects of gender-affirming care, including gender-affirming hormones.
Photo by National Cancer Institute on Unsplash